Breaking News Instant updates and real-time market news.

NVS

Novartis

$85.72

0.13 (0.15%)

05:54
09/13/17
09/13
05:54
09/13/17
05:54

Novartis: Phase III data shows Cosentyx delivered long-lasting skin clearance

Novartis announced first of its kind Phase III data showing Cosentyx delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology, or EADV, Congress in Geneva, Switzerland. By specifically targeting interleukin-17A, or IL-17A, Cosentyx addresses the key cytokine involved in the development of psoriasis. IL-17A plays a significant role in the pathogenesis of plaque psoriasis, psoriatic arthritis, or PsA, and ankylosing spondylitis. Inhibiting IL-17A is important as up to 30% of patients with psoriasis may have PsA.

  • 17

    May

NVS Novartis
$85.72

0.13 (0.15%)

07/26/17
07/26/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Hold from Underperform at Jefferies with analyst Andy Barish saying the current valuation and consensus estimates "now reflect the reality" of Chipotle's path to recovery. 2. Biogen (BIIB) upgraded to Buy from Neutral at Goldman Sachs with analyst Terence Flynn saying the company's balance sheet is under-levered, which provides flexibility, while Aducanumab provides Alzheimer's optionality. 3. DSW (DSW) upgraded to Outperform from Neutral at Wedbush with the firm saying it is more confident that second quarter results will beat expectations and that the company will reiterate its full-year guidance after conducting checks and speaking with the company. 4. Electronic Arts (EA) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post citing a strong fiscal 2019 outlook. 5. Novartis (NVS) upgraded to Overweight from Underweight at Morgan Stanley with analyst Vincent Meunier upgrading the company two notches to Overweight from Underweight following a "massive" reset in consensus expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/17
CANT
08/29/17
NO CHANGE
Target $10
CANT
Overweight
Cantor positive on Amarin after Novartis study results
Cantor Fitzgerald analyst Louise Chen believes the Phase 3 CANTOS study results from Novartis (NVS) support the hypothesis that a long-term drug treatment focused on an anti-inflammatory mechanism in patients with a prior heart attack and inflammatory atherosclerosis can reduce cardiovascular events. In two Phase 3 trials, Amarin's (AMRN) Vascepa affected inflammatory markers including hsCRP and Lp-PLA2 while also improving lipid biomarkers, Chen tells investors in a research note. CANTOS and other recently reported studies help to increase her confidence in a positive and commercial outcome for Amarin's REDUCE-IT trial. The analyst has an Overweight rating on the shares with a $10 price target.
08/31/17
HCWC
08/31/17
NO CHANGE
Target $16
HCWC
Buy
Iovance 'fired another shot across the bow of CAR-Ts,' says H.C. Wainwright
The approval of Novartis' (NVS) Kymriah is a "major leap forward" for oncology and immunotherapy, but there remains "significant room for differentiated products," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note on Iovance Biotherapeutics (IOVA) titled "Pins Set Up: Kite Acquired and Kymriah Approved; TILs Can Knock 'Em Down; Reiterate Buy." The analyst believes Iovance's TILs, or tumor infiltrating lymphocytes, could be significantly differentiated from CAR-Ts like Kymriah. He says the TIL platform has a "significantly" more benign safety profile relative to CAR-Ts and growing evidence that it could effectively target solid tumors, an area where he thinks CAR-Ts continue to struggle. Pantginis thinks Iovance "fired another shot across the bow of CAR-Ts" with last night's ESMO conference abstracts. The company released preliminary data that it can generate highly active TILs from lymphoma tumors, the analyst contends. He reiterates a Buy rating on Iovance with a $16 price target. The shares closed yesterday down 30c to $5.55.
08/31/17
MSCO
08/31/17
NO CHANGE
MSCO
Equal Weight
Gilead response to Kymriah pricing 'confusing,' says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said Novartis' (NVS) pricing of its Kymriah therapy at $475,000 gross puts "some slight pressure" on his model for Juno Therapeutics (JUNO), though he doesn't see it as "that far out of line" with his expectations. While he said it makes sense that Juno saw some pressure yesterday after the pricing news and that bluebird bio (BLUE) closed the gap with Juno, he called Gilead's (GILD) strength yesterday "a bit more confounding" given that Gilead is focused on the same indication as Juno. However, initial DLBCL sales in 2018 for both Gilead and Novartis are likely to drive sentiment, so greater clarity won't be seen until then, added Harrison, who keeps an Equal Weight rating on Juno shares.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

11:20
09/25/17
09/25
11:20
09/25/17
11:20
Periodicals
Amazon acquires '4 Blocks', Deadline Hollywood reports »

Amazon Prime Video…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

11:20
09/25/17
09/25
11:20
09/25/17
11:20
General news
FX Action: USD-JPY »

FX Action: USD-JPY fell…

AAPL

Apple

$151.89

-1.5 (-0.98%)

11:18
09/25/17
09/25
11:18
09/25/17
11:18
Recommendations
Apple analyst commentary  »

Apple iPhone X preorder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

$NSD

NASDAQ Market Internals

11:17
09/25/17
09/25
11:17
09/25/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$151.89

-1.5 (-0.98%)

11:16
09/25/17
09/25
11:16
09/25/17
11:16
Periodicals
Apple's iPhone 8 shows slower adoption than previous models, Localytics reports »

The iPhone 8 and iPhone 8…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

$NYE

NYSE Market Internals

11:16
09/25/17
09/25
11:16
09/25/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
09/25/17
09/25
11:15
09/25/17
11:15
General news
U.S. equities were dented by N. Korean remarks »

U.S. equities were dented…

11:15
09/25/17
09/25
11:15
09/25/17
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
09/25/17
09/25
11:15
09/25/17
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

UN

Unilever; also tag UL

$58.67

0.06 (0.10%)

, UL

Unilever; also tag UN

$57.57

0.13 (0.23%)

11:10
09/25/17
09/25
11:10
09/25/17
11:10
Hot Stocks
Unilever gets into hot South Korean beauty market with acquisition »

Shares of Unilever (UN,…

UN

Unilever; also tag UL

$58.67

0.06 (0.10%)

UL

Unilever; also tag UN

$57.57

0.13 (0.23%)

GS

Goldman Sachs

$230.42

-0.61 (-0.26%)

KHC

Kraft Heinz

$77.52

-1.49 (-1.89%)

EL

Estee Lauder

$107.95

0.365 (0.34%)

LVMUY

LVMH

$55.05

0.208 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

  • 17

    Oct

  • 22

    Oct

UPS

UPS

$117.51

-0.16 (-0.14%)

11:10
09/25/17
09/25
11:10
09/25/17
11:10
Options
Bullish longer-term play in UPS »

Bullish longer-term play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$95.22

-6.895 (-6.75%)

, LH

LabCorp

$150.06

-5.01 (-3.23%)

11:09
09/25/17
09/25
11:09
09/25/17
11:09
Hot Stocks
Medical diagnostics names slide after CMS proposes cuts »

Following the news of the…

DGX

Quest Diagnostics

$95.22

-6.895 (-6.75%)

LH

LabCorp

$150.06

-5.01 (-3.23%)

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

NEO

NeoGenomics

$11.01

0.09 (0.82%)

GHDX

Genomic Health

$30.98

0.13 (0.42%)

VCYT

Veracyte

$8.48

0.18 (2.17%)

VRML

Vermillion

$1.29

0.05 (4.03%)

GNMK

GenMark

$9.52

-0.04 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 30

    Nov

SPY

SPDR S&P 500 ETF Trust

$248.97

-0.47 (-0.19%)

, SPX

S&P 500

11:05
09/25/17
09/25
11:05
09/25/17
11:05
Periodicals
North Korea says firing missiles at U.S 'inevitable,' Guardian says »

According to the…

SPY

SPDR S&P 500 ETF Trust

$248.97

-0.47 (-0.19%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$64.24

-0.09 (-0.14%)

11:05
09/25/17
09/25
11:05
09/25/17
11:05
Options
Carnival call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

CCC

Calgon Carbon

$21.38

-0.025 (-0.12%)

11:04
09/25/17
09/25
11:04
09/25/17
11:04
Downgrade
Calgon Carbon rating change  »

Calgon Carbon downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$35.91

-0.05 (-0.14%)

11:04
09/25/17
09/25
11:04
09/25/17
11:04
Hot Stocks
SpringWorks launches with $103M in Series A funding, rights to 4 programs »

SpringWorks Therapeutics,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 18

    Oct

  • 31

    Oct

  • 08

    Nov

SPX

S&P 500

11:04
09/25/17
09/25
11:04
09/25/17
11:04
General news
North Korea says Trump's comments declaration of war, Bloomberg reports »

North Korean Foreign…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSMT

PriceSmart

$87.60

0.15 (0.17%)

11:04
09/25/17
09/25
11:04
09/25/17
11:04
Initiation
PriceSmart initiated  »

PriceSmart initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

EBS

Emergent BioSolutions

$38.52

0.18 (0.47%)

11:02
09/25/17
09/25
11:02
09/25/17
11:02
Recommendations
Emergent BioSolutions analyst commentary  »

Emergent BioSolutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AIR

AAR Corp.

$37.17

0.23 (0.62%)

10:58
09/25/17
09/25
10:58
09/25/17
10:58
Hot Stocks
AAR Corp. to provide airframe maintenance for Air Canada fleet »

AAR and Air Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNT

Ubiquiti

$54.18

1.52 (2.89%)

10:57
09/25/17
09/25
10:57
09/25/17
10:57
Periodicals
Citron publishes new report on Ubiquiti Networks »

After Citron Research…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Nov

WFC

Wells Fargo

$54.21

-0.0369 (-0.07%)

10:55
09/25/17
09/25
10:55
09/25/17
10:55
Options
Wells Fargo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

GPC

Genuine Parts

$93.73

5.745 (6.53%)

10:55
09/25/17
09/25
10:55
09/25/17
10:55
Conference/Events
Genuine Parts to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Oct

  • 30

    Oct

SSRM

SSR Mining

$10.26

0.16 (1.58%)

10:52
09/25/17
09/25
10:52
09/25/17
10:52
Upgrade
SSR Mining rating change  »

SSR Mining upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$41.13

0.24 (0.59%)

, SCOR

comScore

$29.10

0.25 (0.87%)

10:50
09/25/17
09/25
10:50
09/25/17
10:50
Periodicals
Nielsen sues comScore to prevent Extended TV service, Reuters reports »

Nielsen Holdings (NLSN)…

NLSN

Nielsen

$41.13

0.24 (0.59%)

SCOR

comScore

$29.10

0.25 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.